OxThera Presents Full 24-Month Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients With ESRD

UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), presented data from a 24-month interim analysis of an ongoing phase 2 trial evaluating Oxabact^® in PH type 1 (PH1) patients with end-stage renal disease (ESRD).

Study OC5-OL-01 is evaluating Oxabact in PH1 patients with ESRD. Full data from the 24-month interim analysis of this ongoing study were presented at the American Society of Nephrology Kidney Week, the world’s premier nephrology meeting. The results show that two years of treatment with Oxabact reduced mean plasma oxalate (Pox) by approximately 40% in PH1 patients with ESRD, without intensification in their dialysis regimen.

Learn more about OxThera Presents Full 24-Month Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients With ESRD.